CORRECTED-UPDATE 2-U.S. approves $2 million Novartis gene therapy for rare, deadly muscle disorder

ZURICH/NEW YORK, May 24 - Swiss drugmaker Novartis won U.S. approval for its gene therapy Zolgensma for spinal muscular atrophy (SMA), the leading genetic cause of death in infants, the company said on Friday, a one-time treatment expected to push the pricing boundary for rare diseases to new heights.